Early detection of cancer saves lives.
That is the guiding principal behind Biomoda, Inc., a cancer diagnostics company focused on the development and commercialization of cost-effective, non-invasive, accurate and reproducible diagnostic tests for the early detection of cancer.
Based on molecular marker technology developed at Los Alamos National Laboratory and trademarked under the name CyPath®, Biomoda’s initial product targets lung cancer, the leading cause of cancer deaths worldwide.
The CyPath® diagnostic is currently in clinical trials and can be used only for investigational purposes. Pending FDA approval, Biomoda’s simple in-vitro test for early detection of lung cancer is expected to provide compelling value to the healthcare system through cost savings and improved patient outcomes.
Biomoda is publicly traded under the symbol BMOD. Current research and development operations, laboratory functions and administrative offices are located at 609 Broadway NE in Albuquerque, NM.